Vancouver, British Columbia — Two Vancouver researchers are tackling the deadliest forms of prostate cancer,t he most commonly diagnosed male cancer in Canada, using a brand new field of genomics called computational chemogenomics. This new approach uses computer modeling in virtual 3D to predict how different chemicals or drugs will affect cancer tumours.
The Vancouver Prostate Centre today announced a one-year collaborative project with Novartis Pharmaceutical Corporation. The project will use cutting-edge technology to identify and validate the molecular targets that predict cancer sensitivity or insensitivity to specific inhibitors. Ultimately these insights may enable clinicians to more accurately select patients who are likely to benefit from a particular clinical trial.
The Vancouver Sun is running a series of articles on prostate cancer this week.
The results from a Phase II clinical trial of OGX-011, lead by Dr. Kim Chi, have been published in the Journal of Clinical Oncology. OGX-011 was developed at the Vancouver Prostate Centre, and is now moving to Phase III trials.
Two Vancouver-based “Centres of Excellence in Commercialization in Research” Leverage Resources and Expertise to Develop Anti-Cancer Therapeutics
VANCOUVER, BC – The Centre for Drug Research and Development (CDRD) and the Vancouver Prostate Centre (VPC) today announced that they have signed a preferred collaboration agreement as the two organizations jointly strive to accelerate the discovery, development and commercialization of anti-cancer therapeutics.
OSAKA, JPN – The BC Cancer Agency and the Vancouver Protate Centre announced a formal agreement with Japan-based Takeda Pharmaceutical Co. Ltd. for new drug treatments to fight breast, ovarian and prostate cancers.
The agreement is expected to bring almost $1 million in new cancer research funding to British Columbia.
The Prostate Cancer Foundation (PCF) today announced the funding of 21 new Young Investigator Awards at 17 leading cancer centers in the U.S. and Canada. Designed to encourage the most innovative minds in cancer research to focus their careers on prostate cancer, the awards provide recipients with three years of funding to test transformational research questions for prostate cancer patients. The 2010 Young Investigator Awards represent a new $4.5 million investment in the global cancer research community by PCF.
Investment recognizes world class oncology research and development expertise at BC Cancer Agency and Vancouver Prostate Centre.
MISSISSAUGA, ONTARIO – AstraZeneca Canada is pleased to announce a $500,000 investment to support oncology research and development at the BC Cancer Agency (BCCA). This adds to the $700,000 Vancouver Prostate Centre investment made in January, and represents a significant collaboration with leading British Columbia breast and prostate cancer researchers.
VANCOUVER, BRITISH COLUMBIA – The Vancouver Prostate Centre announced today an extended collaboration with AstraZeneca that sees the Vancouver Prostate Centre receive $700,000 over two years towards research that targets treatment-resistant prostate cancer.
The research, which is being coordinated through the Vancouver Prostate Centre ― a Centre of Excellence for Commercialization and Research ― evaluates AstraZeneca's androgen receptor-targeting small molecules, as well as, molecules that target cell cycle growth to slow, or stop, tumour proliferation in prostate cancer.